ArticleNature medicine2022
Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication.
Open access · greenAbstract read
In one paragraph
Article in Nature medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 161 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
161citing papers in PubMed, 1 pooled it
29.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
161 citing papers in PubMed, 1 synthesis or guideline pooled it, 245 citations in OpenAlex.
- GD2-targeted immunotherapy in pediatric bone sarcomas: a systematic review of emerging strategies and combination approaches.Frontiers in immunology · 2026Pooled it
- A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors.Targeted oncology · 2025Trial
- Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma.Molecular cancer · 2023Trial
- Review
- Genomic landscape and tumor immune microenvironment of osteosarcoma: Bridging mechanistic insights to precision therapeutics.Bone reports · 2026Review
- Alantolactone inhibits T-cell lymphoma progression by suppressing CD47 expression via the PI3K/AKT and ERK signaling pathways.Apoptosis : an international journal on programmed cell death · 2026Article
- Single-cell and spatial omics reveals region-specific plasticity and therapeutic vulnerabilities in metastatic high-risk neuroblastoma.Science advances · 2026Article
- Single-cell transcriptomic atlas-guided NRG3-ERBB4 axis enhances the efficacy of chemo-immunotherapy during induction phase in high-risk neuroblastoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Article
- Understanding and Overcoming Osteosarcoma Heterogeneity.Biomolecules · 2026Review
- Article
- A Biomimetic Self-Adjuvanting Glycoprotein Vaccine Platform Elicits Potent Antitumor Immunity against GD2-Positive Cancers.JACS Au · 2026Article
- Targeted therapies in pediatric oncology: A start.Molecular therapy. Oncology · 2026Review
- Immunotherapy approaches for the treatment of relapsed or progressive medulloblastoma.Journal of neuro-oncology · 2026Review
- Heat up and Destroy: Immunotherapy of "Cold" Tumors Using the Example of Glioblastoma.International journal of molecular sciences · 2026Review
- Transforming Intracerebral Hemorrhage Care with Artificial Intelligence: Opportunities, Challenges, and Future Directions.Diagnostics (Basel, Switzerland) · 2026Review
- GD2-Targeted Minibody-Drug Conjugates Match the Potency of IgG-Based ADCs in a Mouse Cancer Model.International journal of molecular sciences · 2026Article
- Methods and applications of patient-derived organoid models for immune microenvironment and immunotherapy research in multiple cancer types.Experimental hematology & oncology · 2026Review
- Lactylation-related gene signature as a prognostic biomarker for neuroblastoma: insights into tumor progression and immune modulation.Cell & bioscience · 2026Article
- Ir(III) Complexes Convert Cold to Hot Tumors via Ferroptosis/Necroptosis-Driven Immunogenic Cell Death and Photosensitized CD47 Downregulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
101 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors at 7 institutions in 4 countries.
Johanna TheruvathDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
Marie Menard *Departments of Neurology, Pediatrics, and Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, San Francisco, CA, USA.
Benjamin A H Smith *ChEM-H Institute, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-8802-416X
Miles H Linde *Immunology Graduate Program, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-2553-2890
Garry L ColesDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
Guillermo Nicolas DaltonDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
Wei WuDepartment of Radiology, Stanford University School of Medicine, Stanford, CA, USA.
Louise KiruDepartment of Radiology, Stanford University School of Medicine, Stanford, CA, USA.
Alberto DelaidelliBritish Columbia Cancer Agency, Vancouver, BC, Canada.
Elena SotilloStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
John L SilbersteinImmunology Graduate Program, Stanford University School of Medicine, Stanford, CA, USA.
Anna C GeraghtyDepartment of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA.
Allison BanuelosInstitute for Stem Cell Biology and Regenerative Medicine, Stanford, CA, USA.
Molly Thomas RadosevichDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
Shaurya DhingraDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
Sabine HeitzenederStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Aidan TousleyDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
John LattinDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
Peng XuDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
Jing HuangDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
Nicole NasholmDepartments of Neurology, Pediatrics, and Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, San Francisco, CA, USA.
Andy HeDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
Tracy C KuoALX Oncology, Burlingame, CA, USA.ORCID http://orcid.org/0000-0001-6297-8694
Emma R B SangalangALX Oncology, Burlingame, CA, USA.
Jaume PonsALX Oncology, Burlingame, CA, USA.
Amira BarkalInstitute for Stem Cell Biology and Regenerative Medicine, Stanford, CA, USA.
Rachel E BrewerInstitute for Stem Cell Biology and Regenerative Medicine, Stanford, CA, USA.
Kristopher D MarjonInstitute for Stem Cell Biology and Regenerative Medicine, Stanford, CA, USA.
Jose G Vilches-MoureDepartment of Comparative Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Payton L MarshallStanford Medical Scientist Training Program, Stanford University, Stanford, CA, USA.
Ricardo FernandesChinese Academy of Medical Sciences (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.
Michelle MonjeDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-3547-237X
Jennifer R CochranDepartment of Bioengineering, Stanford University Schools of Engineering and Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-6532-9873
Poul H SorensenBritish Columbia Cancer Agency, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0001-7447-2199
Heike E Daldrup-LinkDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-4929-819X
Irving L WeissmanInstitute for Stem Cell Biology and Regenerative Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-9077-7467
Julien SageDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-8928-9968
Ravindra MajetiInstitute for Stem Cell Biology and Regenerative Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-5814-0984
Carolyn R BertozziChEM-H Institute, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-4482-2754
William A WeissDepartments of Neurology, Pediatrics, and Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-2230-9132
Crystal L MackallDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-6323-4304
Robbie G MajznerDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA. rmajzner@stanford.edu.ORCID http://orcid.org/0000-0001-6969-8011
Stanford University · USCalifornia Institute for Regenerative Medicine · USCollaborative Drug Discovery (United States) · USUniversity of California, San Francisco · USBC Cancer Agency · CAChinese Academy of Medical Sciences & Peking Union Medical College · CNStanford Medicine · US
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007365 · NIGMS · STANFORD UNIVERSITY · PI CHUA, KATRIN F · 1985 to 2021
$33.8MMOLECULAR &CELLULAR IMMUNOBIOLOGYT32AI007290 · NIAID · STANFORD UNIVERSITY · PI Sean Curtis Bendall, Olivia M Martinez · 1985 to 2026
$27.0MTumor microenvironment-dependent therapy resistanceP01CA217959 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI JOHN M MARIS · 2017 to 2026
$20.7MLeveraging innovative technologies in basic and clinical cancer researchT32CA009302 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI, Aaron M Newman · 1985 to 2026
$19.1MStem Cell Biology, Cancer Stem Cell Biology, and Cancer ImmunotherapyR35CA220434 · NCI · STANFORD UNIVERSITY · PI WEISSMAN, IRVING L. · 2017 to 2023
$6.7MInvestigating molecular and cellular mechanisms of SCLC development to identify novel therapeutic strategiesR35CA231997 · NCI · STANFORD UNIVERSITY · PI SAGE, JULIEN · 2019 to 2025
$6.2MIntegrating targeted and immunotherapy to treat genetically heterogeneous cancersU01CA217864 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BALMAIN, ALLAN, KRUMMEL, MATTHEW F · 2017 to 2021
$5.1MTargeting the Cancer GlycocalyxR01CA227942 · NCI · STANFORD UNIVERSITY · PI Carolyn Bertozzi · 2019 to 2026
$3.6MNovel therapeutic approaches for enhancing anti-tumor immunity in SCLCU01CA213273 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BYERS, LAUREN AVERETT, HEYMACH, JOHN V. · 2017 to 2021
$3.0MProgrammed Cell Removal (PrCR) by Macrophages: recognition and phagocytosis of target cellsR01AI143889 · NIAID · STANFORD UNIVERSITY · PI WEISSMAN, IRVING L. · 2020 to 2024
$2.0MMyc promoted changes to the glycocalyx in leukemiaF30CA232541 · NCI · STANFORD UNIVERSITY · PI SMITH, BENJAMIN ARTHUR HUMPHERS · 2019 to 2021
$130kNCI NIH HHS F30 CA232541NCI NIH HHS P01 CA217959NCI NIH HHS R01 CA227942NCI NIH HHS R35 CA220434NCI NIH HHS R35 CA231997NCI NIH HHS T32 CA009302NCI NIH HHS U01 CA213273NCI NIH HHS U01 CA217864NIAID NIH HHS R01 AI143889NIAID NIH HHS T32 AI007290NIGMS NIH HHS T32 GM007365
Abstract
The disialoganglioside GD2 is overexpressed on several solid tumors, and monoclonal antibodies targeting GD2 have substantially improved outcomes for children with high-risk neuroblastoma. However, approximately 40% of patients with neuroblastoma still relapse, and anti-GD2 has not mediated significant clinical activity in any other GD2
Indexed as
Bone NeoplasmsCD47 AntigenAnimalsCell Line, TumorHumansImmunotherapyMiceNeoplasm Recurrence, LocalPhagocytosisTumor MicroenvironmentCD47 AntigenCD47 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.